Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Kicks Off TTR Amyloidosis Screening Study

Premium

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced that it has initiated a screening study, called DISCOVERY, to examine the prevalence of transthyretin (TTR) mutations in patients believed to have cardiac amyloidosis, in support of its continued development of an RNAi-based treatment for the disease.

Currently, Alnylam has two drugs in development for transthyretin-mediated amyloidosis. The first, called patisiran, is systemically administered and is being tested for a form of the condition called familial amyloid polyneuropathy, which affects the peripheral nervous system. It is in Phase III testing.

The second, called ALN-TTRsc, is a subcutaneous treatment for forms of the disease called familial amyloidotic cardiomyopathy (FAC) and senile systemic amyloidosis, both of which affect heart tissue. Alnylam hopes to move this drug into Phase III in FAC patients before year-end.

In order to facilitate the development of ALN-TTRsc, Alnylam has initiated the DISCOVERY study, which will enroll up to 1,000 patients with suspected cardiac amyloidosis. Its primary objective is to "further characterize disease features in patients found to have a TTR mutation," Alnylam said.

Results from the study are expected to determine the frequency of TTR mutations in patients with clinical and/or radiological findings of cardiac amyloidosis and identify FAC patients who may be eligible for clinical trials of ALN-TTRsc.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more